



Company Announcement no. 01/2008

To: OMX Nordic Exchange

Hørsholm, Denmark, January 2, 2008

LifeCycle Pharma Initiates Phase II Clinical Trial of LCP-Tacro for the Treatment of Autoimmune Hepatitis

Hørsholm, Denmark, January 02, 2008; LifeCycle Pharma A/S (OMX: LCP) (the "Company" or "LCP"), an emerging specialty pharmaceutical company, today announced that it has initiated a Phase II clinical trial of LCP-Tacro for the treatment of autoimmune hepatitis ("AIH"), also referred to as chronic active hepatitis, a disease which causes a person's body to reject its own liver. The clinical trial is expected to enroll up to 60 patients in up to 12 centers throughout the US and Canada. The Company expects to report top-line clinical trial results in the first half of 2009 (1H09).

"We are excited about participating in the first clinical trial of LCP-Tacro in patients with autoimmune hepatitis (AIH)," said Gerald Y. Minuk, MD, Professor of Medicine & Pharmacology and Head of the Section of Hepatology at the University of Manitoba Health Sciences Centre in Winnipeg. "It's important that physicians have new options for the management of AIH and we think LCP-Tacro could make a real difference in patients' lives."

The clinical trial is a phase II, open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine ("AZA"), each in combination with prednisone, for the treatment of AIH. Up to 60 patients will be randomized (1:1) to receive treatment with LCP-Tacro + prednisone vs. AZA + prednisone.

The Company is pursuing LCP-Tacro for what could be the first FDA-approved drug indicated for the treatment of AIH.

About Autoimmune Hepatitis (AIH)

AIH is a form of hepatitis or liver disease in which the body's immune system attacks liver cells, causing inflammation and a rejection of one's own liver. If untreated, the inflammation can lead to cirrhosis (scarring and hardening) of the liver and eventually liver failure. AIH mainly affects women with a

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSBOLM
WWW.LIFECYCLEPHARMA.COM

TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

page 1 of 2



bimodal age distribution (10 – 30 y and 40 – 50 y). However infants, young children and older adults are also affected.

AIH Current Standard of Treatment

AIH is currently treated with corticosteroids (usually prednisone or prednisolone) and azathioprine in order to reduce the autoimmune reaction and inflammation. Nearly 25% of patients achieve only partial remission with standard treatment or cannot tolerate AZA for various reasons. Disease relapse is frequent after AZA is withdrawn. Other, newer, immunosuppressive drugs in clinical development, such as tacrolimus, are showing promise for people who do not respond to this standard treatment.

About LifeCycle Pharma A/S (“LCP”)

LCP is an emerging specialty pharmaceuticals company that, through innovative technologies, is able to rapidly develop a portfolio of differentiated products to meet the unique needs of key therapeutic markets and patient populations. This includes products for immunosuppression, specifically organ transplantation, and to combat certain cardiovascular diseases. By using its unique and patented delivery technology, MeltDose®, LCP is able to develop drugs with enhanced absorption and thereby increased bioavailability. Currently, the Company has a diversified near- and medium-term pipeline, including a product ready for US commercialization, five product candidates in clinical trials and three in preclinical stages of development. LCP is listed on the OMX Nordic Exchange under the trading symbol (OMX: LCP). For further information, please visit www.lcpharma.com.

Contact:

LifeCycle Pharma A/S
Michael Wolff Jensen, +45 4074-6244
EVP and CFO
MWJ@lcpharma.com

Francesca M. DeMartino
Director, Investor Relations & Corporate Communications
(917) 747-4938; FDM@lcpharma.com

LIFECYCLE PHARMA A/S
KOGLE ALLÉ 4
DK-2970 HØRSHOLM
WWW.LIFECYCLEPHARMA.COM
TEL. +45 7033 3300
FAX +45 3613 0319
CVR. 26 52 77 67
INFO@LCPHARMA.COM

page 2 of 2